{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:59:53Z","timestamp":1792688393446,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T00:00:00Z","timestamp":1628467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","award":["CrossRef Funder ID: 10.13039\/100009945"],"award-info":[{"award-number":["CrossRef Funder ID: 10.13039\/100009945"]}],"id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12325-021-01865-w","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T15:58:34Z","timestamp":1628611114000},"page":"4975-4985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5\u00a0mg\/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct0021313","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00641537","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6989-1054","authenticated-orcid":false,"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-4280","authenticated-orcid":false,"given":"Kottil","family":"Rammohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-4229","authenticated-orcid":false,"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6870-8003","authenticated-orcid":false,"given":"Birgit","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-553X","authenticated-orcid":false,"given":"Dominic","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0997-8817","authenticated-orcid":false,"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"issue":"10130","key":"1865_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336.","journal-title":"Lancet"},{"issue":"13","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1177\/1352458516687402","volume":"23","author":"R Capra","year":"2017","unstructured":"Capra R, Cordioli C, Rasia S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler. 2017;23(13):1757\u201361.","journal-title":"Mult Scler"},{"issue":"10","key":"1865_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S1474-4422(19)30227-3","volume":"18","author":"G Giovannoni","year":"2019","unstructured":"Giovannoni G. Do we have equipoise when it comes to how we treat active multiple sclerosis? Lancet Neurol. 2019;18(10):909\u201311.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1865_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s40265-015-0411-0","volume":"75","author":"H Wiendl","year":"2015","unstructured":"Wiendl H, Meuth SG. Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs. 2015;75(9):947\u201377.","journal-title":"Drugs"},{"issue":"5","key":"1865_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(12)70059-5","volume":"11","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol. 2012;11(5):467\u201376.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1865_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/1352458519845108","volume":"26","author":"M D'Souza","year":"2020","unstructured":"D\u2019Souza M, Heikkil\u00e4 A, Lorscheider J, et al. Electronic Neurostatus-EDSS increases the quality of Expanded Disability Status Scale assessments: experience from two phase 3 clinical trials. Mult Scler. 2020;26(8):993\u20136.","journal-title":"Mult Scler"},{"issue":"11","key":"1865_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444\u201352.","journal-title":"Neurology"},{"issue":"1","key":"1865_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000136645","volume":"31","author":"JF Kurtzke","year":"2008","unstructured":"Kurtzke JF. Historical and clinical perspectives of the Expanded Disability Status Scale. Neuroepidemiology. 2008;31(1):1\u20139.","journal-title":"Neuroepidemiology"},{"issue":"Pt 1","key":"1865_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/brain\/112.1.133","volume":"112","author":"BG Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133\u201346.","journal-title":"Brain"},{"key":"1865_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/B978-0-444-52001-2.00014-5","volume":"122","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, Vukusic S. The clinical course of multiple sclerosis. Handb Clin Neurol. 2014;122:343\u201369.","journal-title":"Handb Clin Neurol"},{"issue":"10","key":"1865_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105123","volume":"9","author":"MG Brown","year":"2014","unstructured":"Brown MG, Asbridge M, Hicks V, et al. Estimating typical multiple sclerosis disability progression speed from clinical observations. PLoS ONE. 2014;9(10): e105123.","journal-title":"PLoS ONE"},{"issue":"5","key":"1865_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"1865_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg S\u00f8rensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594\u2013604.","journal-title":"Mult Scler"},{"key":"1865_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617753365","volume":"11","author":"G Comi","year":"2018","unstructured":"Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord. 2018;11: 1756285617753365.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1865_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2217\/nmt-2018-0023","volume":"8","author":"H Brown","year":"2018","unstructured":"Brown H, Gabriele S, White J. Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA. Neurodegener Dis Manag. 2018;8(6):371\u20136.","journal-title":"Neurodegener Dis Manag"},{"key":"1865_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.msard.2018.11.016","volume":"27","author":"I Eskyte","year":"2019","unstructured":"Eskyte I, Manzano A, Pepper G, et al. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: a critical interpretive synthesis. Mult Scler Relat Disord. 2019;27:370\u20137.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"1865_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2017.12.015","volume":"21","author":"GK Reen","year":"2018","unstructured":"Reen GK, Silber E, Langdon DW. Best methods of communicating clinical trial data to improve understanding of treatments for patients with multiple sclerosis. Value Health. 2018;21(7):762\u20136.","journal-title":"Value Health"},{"issue":"4","key":"1865_CR18","volume":"6","author":"G Bsteh","year":"2020","unstructured":"Bsteh G, Hegen H, Altmann P, et al. Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6(4): 2055217320966344.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"1865_CR19","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340.","journal-title":"JAMA Neurol"},{"key":"1865_CR20","first-page":"1","volume":"13","author":"P Soelberg S\u00f8rensen","year":"2020","unstructured":"Soelberg S\u00f8rensen P, Centonze D, Giovannoni G, et al. Expert opinion on the use of cladribine tablets in clinical practice. Ther Adv Neurol Disord. 2020;13:1\u201317.","journal-title":"Ther Adv Neurol Disord"},{"key":"1865_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G, Cook S, Giovannoni G, et al. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord. 2019;29:168\u201374.","journal-title":"Mult Scler Relat Disord"},{"key":"1865_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419854986","volume":"12","author":"O Stuve","year":"2019","unstructured":"Stuve O, Soelberg S\u00f8rensen P, Leist T, et al. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019;12: 1756286419854986.","journal-title":"Ther Adv Neurol Disord"},{"key":"1865_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"D Baker","year":"2019","unstructured":"Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019;30:176\u201386.","journal-title":"Mult Scler Relat Disord"},{"key":"1865_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","volume":"29","author":"S Cook","year":"2019","unstructured":"Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157\u201367.","journal-title":"Mult Scler Relat Disord"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01865-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:31:25Z","timestamp":1630438285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01865-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01865-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]},"assertion":[{"value":"7 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}